Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
References (0)
Cited by (272)
Endoscopic Diagnosis and Staging of Inflammatory Bowel Disease
2019, Clinical Gastrointestinal EndoscopyInflammatory bowel disease
2019, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal DisordersMicrobiota in pouchitis and de novo crohn’s disease of the ileal pouch
2018, Pouchitis and Ileal Pouch Disorders: A Multidisciplinary Approach for Diagnosis and ManagementClinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases
2017, Digestive and Liver DiseaseDiagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases
2015, GastroenterologyRecognition of preclinical and early disease in axial spondyloarthritis
2014, Rheumatic Disease Clinics of North AmericaCitation Excerpt :It is possible that these patients have subclinical IBD and further studies are required to answer this question. In IBD, the presence of certain antibodies has clinical significance; in Crohn disease, ASCA are associated with younger age of onset and small bowel involvement,50 whereas antineutrophil cytoplasmic antibodies are associated with ulcerative colitis–like features.51 Anti-CBir1 antibodies are associated with fibrostenosing disease and complicated small bowel disease.52
Copyright © 1996 Published by Elsevier Inc.